Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.

Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R

The Journal of clinical endocrinology and metabolism6 May 2008Cited by 200 (Europe PMC)

PMID18460557DOI10.1210/jc.2008-0115PepBankPUB-18460557

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin improved menstrual cyclicity more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved menstrual cycles more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMenstrual cyclicity
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055701
02HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin improved ovulation rate more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved ovulation more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOvulation rate
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055703
03HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin improved free androgen index more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved the free androgen index more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedFree androgen index
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055705
04HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin improved insulin sensitivity more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved insulin sensitivity more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055707
05HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin reduced weight more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin reduced weight more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat. Both EX arms were more effective in promoting weight loss than MET (P = 0.003).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055709
06HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, adding exenatide to metformin reduced abdominal fat more than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin reduced abdominal fat more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAbdominal fat
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055711
07HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide alone promoted greater weight loss than metformin alone.
In plain wordsIn overweight women with PCOS, exenatide alone reduced weight more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight with exenatide monotherapy
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg BID · 24 wkAs given in this study (human).
Source sentences
Summary
Both EX arms were more effective in promoting weight loss than MET (P = 0.003).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
Report a problemFND-1846055713

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin improved menstrual cyclicity more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved menstrual cycles more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMenstrual cyclicity
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055702
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin improved ovulation rate more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved ovulation more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOvulation rate
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055704
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin improved free androgen index more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved the free androgen index more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedFree androgen index
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055706
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin improved insulin sensitivity more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin improved insulin sensitivity more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055708
12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin reduced weight more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin reduced weight more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055710
13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight women with PCOS, exenatide plus metformin reduced abdominal fat more than exenatide alone.
In plain wordsIn overweight women with PCOS, exenatide plus metformin reduced abdominal fat more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAbdominal fat
Study
n: not reported in source
Comparator
Exenatide alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18-40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 microg BID), or COM (MET 1000 mg BID, EX 10 microg BID) for 24 wk.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1846055712

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

RenJi Hospitaln = 18328 Nov 2017 to 31 Jul 2018

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Trial page ClinicalTrials.govUpdated 11 Sept 2019

CompletedPhase 2NCT00344851

Exenatide and Metformin Therapy in Overweight Women With PCOS

Metabolic Center of Louisiana Research Foundationn = 60Jun 2006 to Jun 2007

Polycystic Ovary Syndrome

Trial page ClinicalTrials.govUpdated 11 Jul 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.